Business Description
Wuhan YZY Biopharma Co Ltd
ISIN : CNE1000063C4
Share Class Description:
HKSE:02496: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
02496.Hong Kong IPO Date
2023-09-25Description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.18 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | -0.5 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 4.64 | |||||
| 9-Day RSI | 10.74 | |||||
| 14-Day RSI | 14.95 | |||||
| 6-1 Month Momentum % | -15.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.44 | |||||
| Quick Ratio | 1.41 | |||||
| Cash Ratio | 1.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -14.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -133.68 | |||||
| ROA % | -62.77 | |||||
| ROIC % | -89.27 | |||||
| ROC (Joel Greenblatt) % | -356.04 | |||||
| ROCE % | -131.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.35 | |||||
| Price-to-Tangible-Book | 10.35 | |||||
| EV-to-EBIT | -6.42 | |||||
| EV-to-EBITDA | -6.68 | |||||
| EV-to-FCF | -6.46 | |||||
| Price-to-Net-Current-Asset-Value | 17.33 | |||||
| Price-to-Net-Cash | 57.31 | |||||
| Earnings Yield (Greenblatt) % | -15.58 | |||||
| FCF Yield % | -14.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Wuhan YZY Biopharma Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | |||
| EPS (TTM) (HK$) | -1.138 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 14.95 | ||
| 14-Day ATR (HK$) | 0.012983 | ||
| 20-Day SMA (HK$) | 7.4515 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (HK$) | 7.45 - 19.8 | ||
| Shares Outstanding (Mil) | 193.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Wuhan YZY Biopharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Wuhan YZY Biopharma Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Wuhan YZY Biopharma Co Ltd Frequently Asked Questions
What is Wuhan YZY Biopharma Co Ltd(HKSE:02496)'s stock price today?
The current price of HKSE:02496 is HK$7.45. The 52 week high of HKSE:02496 is HK$19.80 and 52 week low is HK$7.45.
When is next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496)?
The next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496) is .
Does Wuhan YZY Biopharma Co Ltd(HKSE:02496) pay dividends? If so, how much?
Wuhan YZY Biopharma Co Ltd(HKSE:02496) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers